Case description {#section3-2055116919836537}
================

A 10-year-old castrated male domestic shorthair cat presented with a 6 month history of diarrhoea, haemato chezia and mucoid faeces. At a referring hospital, diarrhoea initially resolved with prednisolone and a commercial diet consisting of low- molecular- weight peptides but amoxicillin clavulanic acid. Recurrent diarrhoea responded poorly to prednisolone. The cat also developed chronic kidney disease and cardiomyopathy. It was referred to the Japan Small Animal Medical Center (Saitama, Japan) for endoscopic examination.

At the time of presentation, the cat was markedly lethargic and experienced vomiting once a week and large bowel diarrhoea 2--3 times daily. Its body weight had decreased significantly, from 5.6 kg to 4.75 kg. A faecal examination yielded unremarkable results. Serum biochemical tests revealed an elevated creatinine level (2.6 mg/dl). Abdominal radiographs were normal. Ultrasonography revealed moderately increased intestinal wall thickness (4.8 mm) from the ascending to proximal descending colon ([Figure 1](#fig1-2055116919836537){ref-type="fig"}). Enlarged right colic and jejunal lymph nodes were noted (9.5 mm × 7.1 mm and 10.4 mm × 6.1 mm, respectively). Endoscopic examination revealed partial circumferential narrowing of the transverse colon and friable colonic mucosa with multiple haemorrhagic regions ([Figure 2](#fig2-2055116919836537){ref-type="fig"}). The mucosa of the duodenum and jejunum was mildly oedematous. The thickness of the oesophageal and gastric mucosa was within normal limits. Mucosal tissue specimens were obtained from the stomach, duodenum and colon. The collected tissue samples were fixed in 10% buffered formalin and subjected to histopathological examination.

![Ultrasonographic appearance of the jejunum (arrowhead) and ascending colon on a transverse section revealing increased wall thickness to 4.8 mm (arrow)](10.1177_2055116919836537-fig1){#fig1-2055116919836537}

![Endoscopic image of the transverse colon. Multiple haemorrhagic lesions are apparent in the friable mucous membrane](10.1177_2055116919836537-fig2){#fig2-2055116919836537}

Histological examination with haematoxylin and eosin staining (HE) revealed marked ulceration of the colonic mucosa; marked alteration in the normal glandular architecture was observed in the lamina propria ([Figure 3](#fig3-2055116919836537){ref-type="fig"}). The lesions consisted of marked transmural infiltration of foamy macrophages accompanied by neutrophils, plasma cells and lymphocytes ([Figure 4](#fig4-2055116919836537){ref-type="fig"}). Apart from the colonic lesion, marked infestation of mucosa spirochetes was observed in the stomach. Duodenal lesions were unremarkable. A provisional diagnosis of granulomatous colitis (GC) was made based on the histopathological appearance (HE) at day 7.

![Colon. Lower magnification reveals thickening of the colonic wall. Marked ulceration of the colonic mucosa and distortion of the glandular architecture in the lamina propria are identified. Haematoxylin and eosin](10.1177_2055116919836537-fig3){#fig3-2055116919836537}

![Colon. Marked transmural infiltration of foamy macrophages (arrow) is accompanied by neutrophils, plasma cells and lymphocytes](10.1177_2055116919836537-fig4){#fig4-2055116919836537}

Owing to its rarity in cats, additional stains and immunohistochemistry were performed for definitive diagnosis. The infiltrating macrophages were predominantly periodic acid--Schiff (PAS) positive ([Figure 5](#fig5-2055116919836537){ref-type="fig"}). Warthin--Starry, Ziehl--Neelsen and gram stains identified intracytoplasmic non-acid-fast, gram-negative bacilli in the macrophages on tissue section ([Figure 6](#fig6-2055116919836537){ref-type="fig"}). The infiltration of macrophages and *Escherichia coli* colonisation were further confirmed by immunohistochemical analyses. Immunohistochemistry revealed marked infiltration of CD204^+^ Iba-1^+^ macrophages and colonisation of *E coli* in the granulomatous lesions ([Figure 7](#fig7-2055116919836537){ref-type="fig"}). In view of these findings, a final diagnosis of GC was made at day 21.

![Colon. Infiltration of periodic acid--Schiff stain-positive macrophages in the lamina propria](10.1177_2055116919836537-fig5){#fig5-2055116919836537}

![Colon. Colonisation of bacilli is identified in the granulomatous lesion. Warthin--Starry stain](10.1177_2055116919836537-fig6){#fig6-2055116919836537}

![Colon. Numerous bacilli are identified in the colonic lamina propria. Immunohistochemistry for *Escherichia coli* lipopolysaccharide](10.1177_2055116919836537-fig7){#fig7-2055116919836537}

At day 0, prior to a definitive diagnosis of GC with histopathology and immunohistochemistry, the cat was initially treated with prednisolone (1 mg/kg q24h), famotidine (1 mg/kg q24h), metoclopramide (0.25 mg/kg q12 h) and probiotics (*Streptococcus faecalis* 129 BIO 3B-R \[Biofermin-R; Biofermin Pharmaceutical\]; half tablet q24h) for 4 weeks. The cat was fed a therapeutic diet (Renal Support; Royal Canin). The initial treatment appeared to only partially improve clinical signs. The cat had semi-formed stools twice daily, with inconsistent solid stools. Body weight decreased from 4.75 kg to 4.45 kg within the first 28 days of treatment.

Following the definitive diagnosis, additional colonoscopic tissue sampling was performed for bacterial culture and sensitivity at day 28. After saline wash, a homogenised sample was subjected to bacterial culture. Attempts to isolate bacteria on culture media yielded enrofloxacin-sensitive *E coli* (2+). Treatment with enrofloxacin was also initiated at day 28. The animal was prescribed enrofloxacin (5 mg/kg q24h for 13 weeks), as recommended in dogs,^[@bibr1-2055116919836537]^ prednisolone (0.5 mg/kg q24h for 5 weeks), famotidine (1 mg/kg q24h for 2 weeks), metoclopramide (0.25 mg/kg q12h for 13 weeks) and the aforementioned probiotic half- tablet (q24h for 13 weeks). The cat more consistently produced solid or semi-formed stools once daily and its body weight increased to 4.75 kg by day 42.

The cat's body weight increased to 5.0 kg and formed solid stools twice daily by day 63. Although ultrasound examinations at day 119 showed persistent wall thickening of the ascending and transverse colon (4.6 mm), enrofloxacin was discontinued because the thickness of the right colic lymph nodes was within the normal limit. At day 207, approximately 3 months after cessation of the first course of enrofloxacin, recurrent diarrhoea was noted once every 3 days. Upon examination at day 234, the cat's body weight was found to have decreased to 4.8 kg. Ultrasonography revealed thickening of the ascending and transverse colonic wall (4.6 mm), and moderately enlarged right colic lymph nodes (8 mm). Serum biochemical tests revealed increased creatinine (3.4 mg/dl) and urea nitrogen (34.5 mg/dl) levels. The cat was treated with enrofloxacin (5 mg/kg q24h for 15 weeks and q48h for the following 8 weeks). Faecal consistency dramatically improved by day 244. However, the cat experienced another episode of diarrhoea at day 751, approximately 12 months after cessation of the second course of enrofloxacin. Enrofloxacin was reinitiated (5 mg/kg q24h for 4 weeks) and a positive clinical response was noted by day 755.

The cat has been free of clinical signs for the following 7 months and has been off enrofloxacin without recurrence for 5 months (day 950). Enrofloxacin-associated retinal degeneration was not observed in the current case.

Discussion {#section4-2055116919836537}
==========

An enteropathy called GC, or histiocytic ulcerative colitis, is characterised by granulomatous inflammation of the colonic mucosa, lamina propria and submucosa, with marked transmural infiltration of PAS-positive macrophages.^[@bibr2-2055116919836537],[@bibr3-2055116919836537]^ PAS-positive material is considered to be glycoprotein from bacterial cell walls.^[@bibr4-2055116919836537]^ GC has been frequently reported in dogs; however, only a limited number of cases have been reported in cats.^[@bibr4-2055116919836537]^ Clinical presentation, and macroscopic and microscopic findings in the present study were consistent with those described in dogs.^[@bibr2-2055116919836537],[@bibr3-2055116919836537],[@bibr5-2055116919836537]^ In canine cases, macrophage heterogeneity suggests a difference in function compared with healthy individuals.^[@bibr6-2055116919836537]^

Although the pathogenesis is not well understood, recent studies have identified *E coli* in canine patients.^[@bibr5-2055116919836537],[@bibr7-2055116919836537],[@bibr8-2055116919836537]^ There are phylogenetic similarities between the *E coli* strain obtained from Boxer dog GC, and adherent and invasive *E coli* (AIEC) in human Crohn's disease.^[@bibr8-2055116919836537]^ AIEC is able to replicate within epithelial cells and macrophages without inducing host cell death.^[@bibr9-2055116919836537]^ AIEC has been isolated from the feline intestine at an exceptionally high frequency (82%),^[@bibr10-2055116919836537]^ and the association between AIEC and feline GC needs to be further investigated. In the current case, identification of *E coli* in the granulomatous lesion was consistent with a previous feline study that reported bacilli within the phagocytic vacuoles of macrophages.^[@bibr4-2055116919836537]^ Although not performed in the current case study, identification of the *E coli* strain and repeated histopathological evaluation would be valuable to understanding the nature of feline GC.

As demonstrated in canine case studies,^[@bibr11-2055116919836537]^ regression of clinical signs following antibacterial treatment in the present case suggests a critical role of *E coli* in feline GC. The cat responded well to intermittently administered enrofloxacin when it had semi-formed stools or diarrhoea. Dramatic improvement in faecal consistency was noted within 2 weeks of antibacterial treatment, which is consistent with previous investigations involving dogs.^[@bibr1-2055116919836537]^ In dogs, at least 6--8 weeks of treatment at doses of 5--10 mg/kg body weight q24h is recommended.^[@bibr1-2055116919836537]^ However, response to antibacterials varies among individual dogs,^[@bibr1-2055116919836537],[@bibr11-2055116919836537]^ and it appears that antibacterial resistance significantly affects clinical outcomes.^[@bibr12-2055116919836537]^ Although the current single case was insufficient to determine the factors affecting clinical outcomes in cats, a future case series would help in determining the optimal use of antibacterials in feline GC.

Over-representation of the Boxer dog breed suggests that GC might be a breed-specific disease; however, it has also been reported in other canine breeds.^[@bibr2-2055116919836537],[@bibr5-2055116919836537],[@bibr7-2055116919836537],[@bibr13-2055116919836537][@bibr14-2055116919836537][@bibr15-2055116919836537]--[@bibr16-2055116919836537]^ While dogs \<4 years of age are typically affected by GC,^[@bibr2-2055116919836537]^ in this case and the other case study middle-aged cats were affected.^[@bibr4-2055116919836537]^ The rarity of the disease in cats may suggest variation in hereditary susceptibility to *E coli*-related GC between dogs and cats.

The present case report described the case of a cat with *E coli*-related GC that regressed following long-term treatment with enrofloxacin. Clinical presentation, and endoscopic and microscopic findings closely resembled those described in dogs. Immunohistochemically, *E coli* was detected within granulomatous lesions, and resolution of gastrointestinal clinical signs following antibacterial treatment may reflect the critical role of *E coli* in feline GC. The rarity of the disease in cats may suggest substantial differences in host susceptibility to *E coli*-induced GC. Together with our findings, additional cases will enable a better understanding of the clinical nature of GC in cats.

Conclusions {#section5-2055116919836537}
===========

GC should be included in the differential diagnoses in feline cases with marked submucosal infiltration of macrophages in the colon that respond poorly to immunosuppressive and dietary treatment. In such cases, further immunohistochemical identification of *E coli* and treatment with enrofloxacin may be suggested.
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